|1.||Sickle Cell Anemia (Hemoglobin S Disease)
|4.||Glucosephosphate Dehydrogenase Deficiency
|5.||Falciparum Malaria (Plasmodium falciparum Malaria)
|1.||Connes, Philippe: 12 articles (11/2013 - 12/2005)|
|2.||Tripette, Julien: 10 articles (11/2013 - 01/2007)|
|3.||Hue, Olivier: 10 articles (01/2013 - 03/2003)|
|4.||Hardy-Dessources, Marie-Dominique: 7 articles (01/2013 - 03/2003)|
|5.||Deloron, Philippe: 7 articles (01/2013 - 10/2002)|
|6.||Féasson, Léonard: 6 articles (05/2015 - 02/2010)|
|7.||Martin, Cyril: 6 articles (08/2012 - 01/2007)|
|8.||Thiriet, Patrice: 6 articles (08/2012 - 01/2007)|
|9.||Etienne-Julan, Maryse: 6 articles (01/2012 - 03/2003)|
|10.||Oyono-Enguéllé, Samuel: 5 articles (05/2015 - 02/2010)|
11/01/2002 - "51% of sickle cell trait and 86% of control cases had mild to severe anaemia which improved with iron therapy in trait cases. "
07/01/2012 - "Study concludes low serum iron associated with alpha deletions and high level of HbF associated with Xmn-1 polymorphism in sickle cell traits. "
07/01/2012 - "Here we are presenting the alpha deletion in association with low serum iron and increased HbF level with Xmn-1 carriers in sickle cell traits. "
04/01/2008 - "Twenty two sickle cell anaemia (SS), 47 sickle cell trait (AS) and 150 normal control (AA) individuals who were iron deficient, were given iron therapy for a period of 12 wk and the laboratory investigations were repeated at the 13th wk. Sixty seven per cent of subjects with sickle cell anaemia and 26 per cent with sickle cell trait had elevated ZPP/H ratios (>80 micromol/mol) as against 22.8 per cent of normal individuals. "
10/01/1982 - "The reduced frequency of iron deficiency anaemia in sickle cell trait may be explained by increased iron absorption, or alternatively by reduced iron requirements and a lower risk of discrepancy between iron supply and demand. "
|2.||Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA
01/01/2010 - "Blood donation from glucose-6-phosphate dehydrogenase (G6PD)-deficient and sickle cell trait (SCT) donors might alter the quality of the donated blood during processing, storage or in the recipient's circulatory system. "
05/03/1979 - "The overall frequency of sickle-cell trait was 7.8 per cent and of glucose-6-phosphate dehydrogenase dificiency 11.2 per cent. "
06/01/1968 - "Deficiency of erythrocyte glucose-6-phosphate dehydrogenase and sickle cell trait: a survey of Mahar students at Aurangabad, Maharashtra."
01/01/2012 - "Sickle cell trait, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and α(+)-thalassaemia were observed in 2.8%, 9.6%, and 15.1%, respectively. "
03/01/2009 - "Genes for thalassaemia, haemoglobin S, Glucose-6-phosphate dehydrogenase which confer resistance to malaria are found in high frequencies in Nigeria, 25% of the population being carriers of the sickle cell trait while another 25% are hemizygous for the G6PD gene. "
11/01/2013 - "The goal of the present study was to test whether fasting during the holy period of Ramadan may disturb blood rheology in sickle cell trait (SCT) carriers more than in a group of subjects with normal hemoglobin. "
12/05/2008 - "This study compared the nocturnal autonomic nervous system (ANS) activity in seven sickle cell trait (SCT) carriers and six subjects with normal hemoglobin in response to exercise Sympathetic and parasympathetic indices of nocturnal ANS were measured in the two groups before and 24 and 48 h after a strenuous exercise consisting of the repetition of three maximal exercise bouts. "
01/01/2008 - "This study investigated the cardioventilatory responses during heavy exercise in sickle cell trait carriers (SCTc) and subjects with normal hemoglobin (control group). "
11/01/2007 - "This study investigated 1) whether ventilatory and lactic thresholds (VT and LT, respectively) are different in sickle cell trait carriers (SCTc) and subjects with normal hemoglobin (control group), and 2) whether the first LT and VT and the second LT and VT are respectively coincident in the two populations. "
12/01/2002 - "The aim of the study is to assess the pregnancy outcome among Omani women with sickle cell trait (SCT), and to compare it with a control group of Omani women with normal hemoglobin. "
12/01/2011 - "No deaths from the condition have been reported previously, whereas death after vigorous physical activity in individuals with sickle cell trait (hemoglobin AS) has been described in a few case reports. "
02/01/2008 - "We conclude that the H/H131 genotype and H131 allele rather than Hb AS genotype (sickle cell trait patients) appear to associate with the Fulani ethnic group."
11/01/2007 - "Sickle cell trait (hemoglobin AS) is the most common genotype and has traditionally been considered a benign condition. "
09/01/2004 - "BACKGROUND Red blood cell (RBC) components from donors with sickle cell trait (Hb AS) often occlude white blood cell (WBC) reduction filters. "
07/01/2003 - "To determine whether sickle cell trait (hemoglobin AS) is associated with abnormalities in the brain of asymptomatic children. "
07/01/2003 - "Among children with sickle cell trait, percentage of hemoglobin S was significantly greater in children who had tortuosity than percentage of hemoglobin S in children who had normal blood vessels at MR angiography (P <.03). "
11/01/2010 - "These studies included 96 patients with hemoglobin SS, SC, and sickle cell trait (AS). "
01/01/2015 - "Sickle cell trait (heterozygosity for hemoglobin S, n = 268) was compared with no sickle cell trait (n = 3748). "
02/24/2011 - "Observed differences indicate the effect of the polymerization of sickle hemoglobin as well as possible changes in the organization of the cell cytoskeleton associated with the sickle cell trait."
12/01/2005 - "Of 1,906 children screened preoperatively, 79 (4.1%) were diagnosed as having sickle cell trait and three (0.16%) as having some form of SCD: one had homozygous hemoglobin S and two had sickle-hemoglobin C disease. "
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/01/2003 - "Sickle cell trait, glucose-6-phosphate dehydrogenase deficiency, and mutation in the promoter region of tumor necrosis factor (TNF(-376A/-238A)) were significantly associated with asymptomatic P. "
10/01/2000 - "We found the following frequencies: blood group O (0.54), sickle-cell trait (0.23), G6PD deficiency (0.09), MBP gene mutations (0.34), TNF-alpha promoter mutations (at positions -238: 0.17 and -308: 0.22) and NOS2 promoter mutation (0.18). "
03/01/1999 - "In contrast to the sickle cell trait, the TNF alpha promotor polymorphism appeared not to have any protective effect on malaria in this study, and its importance in other unspecified fever-causing diseases in this population needs further investigation."
03/01/1999 - "To investigate the effects of host polymorphisms on malaria morbidity and infection, the frequency distributions of TNF alpha promotor gene and sickle cell trait were studied in infants in an area highly endemic for Plasmodium falciparum transmission in Tanzania. "
10/01/2000 - "Several human genetic factors, including red blood cell polymorphisms (ABO blood group, sickle-cell trait, G6PD deficiency) as well as point mutations in the mannose binding protein (MBP) and in the promoter regions of both the TNF-alpha and NOS2 genes, influence the severity of disease due to infection with Plasmodium falciparum. "
|7.||Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
|8.||Complement Receptors (Complement Receptor)IBA
08/01/2006 - "The past few years have seen significant progress towards achieving this goal for some of the best-known malaria resistance genes that determine the structure or function of red blood cells: Gerbich blood group antigen negativity; polymorphisms of the complement receptor genes (most notably CR1); Southeast Asian ovalocytosis; pyruvate kinase deficiency; haemoglobin E; the sickle cell trait; and alpha-thalassaemia are all examples. "
11/01/2010 - "Some of the mechanisms underlying protection against this disease are described in this review for hemoglobin-inherited disorders (thalassemia, sickle-cell trait, HbC and HbE), erythrocyte polymorphisms (ovalocytosis and Duffy blood group), enzymopathies (G6PD deficiency and PK deficiency) and immunogenetic variants (HLA alleles, complement receptor 1, NOS2, tumor necrosis factor-α promoter and chromosome 5q31-q33 polymorphisms)."
|10.||Proteins (Proteins, Gene)IBA
06/25/2003 - "However, the sickle cell trait, fever and the use of chemoprophylaxis did not have a significant association with the presence of P. "
03/01/2007 - "Sickle-cell trait confers protection against malaria while homozygote sickle-cell disease (SCD) patients are at greater risk of malaria infection, hence the use of malaria chemoprophylaxis in SCD patients. "
|3.||Transplantation (Transplant Recipients)
|4.||Cardiopulmonary Bypass (Heart-Lung Bypass)
10/01/2004 - "Con: Exchange transfusion is not required for sickle cell trait patients undergoing cardiopulmonary bypass."
10/01/2004 - "Pro: Exchange transfusion is required for sickle cell trait patients undergoing cardiopulmonary bypass."
10/01/1996 - "[Cardiac surgery using cardiopulmonary bypass in a patient with sickle-cell trait]."
11/01/1984 - "Hypothermic cardiopulmonary bypass in a patient with sickle-cell trait."
02/01/2006 - "Data of 43 patients with sickle cell traits and 2 with sickle cell disease, who were operated on under cardiopulmonary bypass and cold cardioplegic arrest in a tertiary center from the beginning of 1995 to the end of 2004, were retrospectively analyzed. "
02/01/2012 - "Similarly, the renal morbidity and outcome after transplant in patients with sickle cell trait is also unclear. "
12/01/2007 - "We report a case of living-related renal transplant, in which both the recipient and the donor had sickle cell trait, and the postoperative course for both was uneventful."
12/01/2007 - "Kidney transplant from sickle cell trait donor to sickle cell trait recipient."
10/01/2012 - "Priapism in an infant with sickle cell trait after cardiac transplant."
02/01/2012 - "There is little evidence concerning living donation in donors with sickle cell disease or sickle cell trait, either for the donor health or for the graft outcome, and there are no United Kingdom guidelines. "